Literature DB >> 29879704

Characterization of Siglec-8 Expression on Lavage Cells after Segmental Lung Allergen Challenge.

Mats W Johansson1, Elizabeth A Kelly2, Christopher L Nguyen1, Nizar N Jarjour2, Bruce S Bochner3.   

Abstract

BACKGROUND: Siglec-8 is present at a high level on human blood eosinophils and low level on blood basophils. Engagement of Siglec-8 on blood eosinophils causes its internalization and results in death. Siglec-8 is a potential therapeutic target in eosinophilic asthma.
OBJECTIVES: The aim of this study was to determine Siglec-8 levels on eosinophils and basophils recruited during lung inflammation.
METHOD: We analyzed surface Siglec-8 by flow cytometry on cells obtained by bronchoalveolar lavage (BAL) 48 h after segmental lung allergen challenge of human subjects with mild allergic asthma and used confocal microscopy to compare Siglec-8 distribution on BAL and blood eosinophils.
RESULTS: Like their blood counterparts, BAL eosinophils had high unimodal surface Siglec-8, while BAL basophils had lower but detectable surface Siglec-8. BAL macrophages, monocytes, neutrophils, and plasmacytoid dendritic cells did not express surface Siglec-8. Microscopy of freshly isolated blood eosinophils demonstrated homogeneous Siglec-8 distribution over the cell surface. Upon incubation with IL-5, Siglec-8 on the surface of eosinophils became localized in patches both at the nucleopod tip and at the opposite cell pole. BAL eosinophils also had a patchy Siglec-8 distribution.
CONCLUSIONS: We conclude that 48 h after segmental allergen challenge, overall levels of Siglec-8 expression on airway eosinophils resemble those on blood eosinophils, but with a patchier distribution, a pattern consistent with activation. Thus, therapeutic targeting of Siglec-8 has the potential to impact blood as well as lung eosinophils, which may be associated with an improved outcome in eosinophilic lung diseases.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Airway; Basophil; Blood; Eosinophil; Flow cytometry

Mesh:

Substances:

Year:  2018        PMID: 29879704      PMCID: PMC6105496          DOI: 10.1159/000488951

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  36 in total

1.  IL-33 enhances Siglec-8 mediated apoptosis of human eosinophils.

Authors:  Ho Jeong Na; Sherry A Hudson; Bruce S Bochner
Journal:  Cytokine       Date:  2011-11-12       Impact factor: 3.861

2.  Leveraging Siglec-8 endocytic mechanisms to kill human eosinophils and malignant mast cells.

Authors:  Jeremy A O'Sullivan; Daniela J Carroll; Yun Cao; Adriano N Salicru; Bruce S Bochner
Journal:  J Allergy Clin Immunol       Date:  2017-07-20       Impact factor: 10.793

3.  Identification of SAF-2, a novel siglec expressed on eosinophils, mast cells, and basophils.

Authors:  K K Kikly; B S Bochner; S D Freeman; K B Tan; K T Gallagher; K J D'alessio; S D Holmes; J A Abrahamson; C L Erickson-Miller; P R Murdock; H Tachimoto; R P Schleimer; J R White
Journal:  J Allergy Clin Immunol       Date:  2000-06       Impact factor: 10.793

4.  Dissection of the hyperadhesive phenotype of airway eosinophils in asthma.

Authors:  Steven R Barthel; Nizar N Jarjour; Deane F Mosher; Mats W Johansson
Journal:  Am J Respir Cell Mol Biol       Date:  2006-04-06       Impact factor: 6.914

5.  Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis.

Authors:  Esra Nutku; Hideyuki Aizawa; Sherry A Hudson; Bruce S Bochner
Journal:  Blood       Date:  2003-02-27       Impact factor: 22.113

6.  Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma.

Authors:  Elizabeth A Kelly; Stephane Esnault; Lin Ying Liu; Michael D Evans; Mats W Johansson; Sameer Mathur; Deane F Mosher; Loren C Denlinger; Nizar N Jarjour
Journal:  Am J Respir Crit Care Med       Date:  2017-12-01       Impact factor: 21.405

7.  Mepolizumab and exacerbations of refractory eosinophilic asthma.

Authors:  Pranabashis Haldar; Christopher E Brightling; Beverley Hargadon; Sumit Gupta; William Monteiro; Ana Sousa; Richard P Marshall; Peter Bradding; Ruth H Green; Andrew J Wardlaw; Ian D Pavord
Journal:  N Engl J Med       Date:  2009-03-05       Impact factor: 91.245

8.  Sialic acid-binding immunoglobulin-like lectin 8 (Siglec-8) is an activating receptor mediating β2-integrin-dependent function in human eosinophils.

Authors:  Daniela J Carroll; Jeremy A O'Sullivan; David B Nix; Yun Cao; Michael Tiemeyer; Bruce S Bochner
Journal:  J Allergy Clin Immunol       Date:  2017-09-06       Impact factor: 10.793

Review 9.  The Biology of Eosinophils and Their Role in Asthma.

Authors:  Claire N McBrien; Andrew Menzies-Gow
Journal:  Front Med (Lausanne)       Date:  2017-06-30

Review 10.  Regulation of Eosinophil Recruitment and Activation by Galectins in Allergic Asthma.

Authors:  Savita P Rao; Xiao Na Ge; P Sriramarao
Journal:  Front Med (Lausanne)       Date:  2017-05-31
View more
  10 in total

1.  AK002, a Humanized Sialic Acid-Binding Immunoglobulin-Like Lectin-8 Antibody that Induces Antibody-Dependent Cell-Mediated Cytotoxicity against Human Eosinophils and Inhibits Mast Cell-Mediated Anaphylaxis in Mice.

Authors:  Bradford A Youngblood; Emily C Brock; John Leung; Rustom Falahati; Paul J Bryce; Jessica Bright; Jason Williams; Leonard D Shultz; Dale L Greiner; Michael A Brehm; Christopher Bebbington; Nenad Tomasevic
Journal:  Int Arch Allergy Immunol       Date:  2019-08-09       Impact factor: 2.749

Review 2.  Eosinophil and mast cell Siglecs: From biology to drug target.

Authors:  Jeremy A O'Sullivan; Alan T Chang; Bradford A Youngblood; Bruce S Bochner
Journal:  J Leukoc Biol       Date:  2020-01-22       Impact factor: 4.962

3.  An anti-siglec-8 antibody depletes sputum eosinophils from asthmatic subjects and inhibits lung mast cells.

Authors:  Sheena C Kerr; Jeanmarie R Gonzalez; Julia Schanin; Michael C Peters; Bart N Lambrecht; Emily C Brock; Annabelle Charbit; K M Ansel; Bradford A Youngblood; John V Fahy
Journal:  Clin Exp Allergy       Date:  2020-07-08       Impact factor: 5.018

4.  First Evidence for a Role of Siglec-8 in Breast Cancer.

Authors:  Anna Trebo; Nina Ditsch; Tom Degenhardt; Christina Kuhn; Martina Rahmeh; Elisa Schmoeckel; Doris Mayr; Bastian Czogalla; Thomas Kolben; Sarah Meister; Sven Mahner; Udo Jeschke; Anna Hester
Journal:  Int J Mol Sci       Date:  2021-02-18       Impact factor: 5.923

Review 5.  Modulation of Immune Tolerance via Siglec-Sialic Acid Interactions.

Authors:  Joyce Lübbers; Ernesto Rodríguez; Yvette van Kooyk
Journal:  Front Immunol       Date:  2018-12-07       Impact factor: 7.561

Review 6.  Discovery, Function, and Therapeutic Targeting of Siglec-8.

Authors:  Bradford A Youngblood; John Leung; Rustom Falahati; Jason Williams; Julia Schanin; Emily C Brock; Bhupinder Singh; Alan T Chang; Jeremy A O'Sullivan; Robert P Schleimer; Nenad Tomasevic; Christopher R Bebbington; Bruce S Bochner
Journal:  Cells       Date:  2020-12-24       Impact factor: 6.600

Review 7.  Function of Macrophages in Disease: Current Understanding on Molecular Mechanisms.

Authors:  Chunye Zhang; Ming Yang; Aaron C Ericsson
Journal:  Front Immunol       Date:  2021-03-08       Impact factor: 7.561

8.  A FACS-based approach to obtain viable eosinophils from human adipose tissue.

Authors:  James D Hernandez; Ben Yi Tew; Ting Li; Gerald C Gooden; Hamza Ghannam; Mia Masuda; James Madura; Bodour Salhia; Elizabeth A Jacobsen; Eleanna De Filippis
Journal:  Sci Rep       Date:  2020-08-06       Impact factor: 4.379

9.  Bidirectional crosstalk between eosinophils and esophageal epithelial cells regulates inflammatory and remodeling processes.

Authors:  Julia L M Dunn; Julie M Caldwell; Adina Ballaban; Netali Ben-Baruch Morgenstern; Mark Rochman; Marc E Rothenberg
Journal:  Mucosal Immunol       Date:  2021-05-10       Impact factor: 7.313

10.  Isolation, identification, and characterization of the human airway ligand for the eosinophil and mast cell immunoinhibitory receptor Siglec-8.

Authors:  Anabel Gonzalez-Gil; T August Li; Ryan N Porell; Steve M Fernandes; Haley E Tarbox; Hyun Sil Lee; Kazuhiro Aoki; Michael Tiemeyer; Jean Kim; Ronald L Schnaar
Journal:  J Allergy Clin Immunol       Date:  2020-08-11       Impact factor: 10.793

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.